Not every issue of ‘The Renewal’ arrives with a clinical result to report. This one doesn’t. What it has instead is something the previous eight issues have been building toward: a clear account of the regulatory conditions that determine whether the progress described in those issues reaches patients safely. A peer-reviewed paper published in PNAS in March argues those conditions are weakening. The FDA issued a warning letter in February that shows the enforcement mechanism still exists. The question the issue asks is whether those two things can both be true at once, and for how long.

The FDA has never had full visibility into the stem cell clinic market. Its authority over human cell and tissue products operates through a framework - the HCT/P regulations, codified in 21 CFR 1271 - that was written before the commercial clinic market reached its current scale. For years, the agency operated under a period of enforcement discretion, during which it sent warning letters and pursued legal action against a small number of high-risk operators while the broader market continued to expand. That discretion period formally ended in 2021. By then, the market it was meant to constrain had already grown into something the warning letter mechanism was not designed to address at volume.

The PNAS perspective published in March 2026 by independent researchers documents this gap and argues it is widening. The authors identify three converging developments: a 2025 FDA draft guidance on expedited approval pathways for regenerative medicine therapies, which they read as a signal of further deregulation; stated policy positions that characterise existing enforcement as overly aggressive; and a clinic market that, by the researchers' account, has responded to each period of reduced oversight with continued growth rather than compliance.

What the PNAS authors are describing is a specific consequence for specific people: patients who encounter a clinic marketing umbilical cord-derived treatments for arthritis, Parkinson's disease, sports injuries, or chronic pain, with no way to determine whether those claims have any regulatory basis, in an environment where the signal that distinguishes legitimate providers from illegitimate ones is becoming harder to read.

Those signals: the FDA warning letter, the enforcement action, the absence of approved status. They are the primary navigational tools available to a patient trying to separate legitimate providers from illegitimate ones. The February 2026 warning letter to Dynamic Stem Cell Therapy shows the mechanism still functions. A market of 2,750 clinics shows the scale at which it must function to make any difference.

A faster approval pathway is potentially good for patients waiting for real treatments. If the same loosening reduces the evidence standard that distinguishes real treatments from marketed ones, the benefit goes to clinics more than to patients.

The PNAS authors conclude there is no justification for reducing FDA oversight of stem cell clinics given the current evidence of patient harm. That is a scientific and public health argument. Whether it is acted on is a policy question this newsletter is not in a position to answer. What it can do is make the argument visible, and give readers the tools to ask the right question when they encounter a clinic that calls itself regulated.

Cell Stem Cell, November 24, 2025 - Icahn School of Medicine at Mount Sinai

This study is six months old. It is included here because it was newly publicised by Mount Sinai's communications team this week and because it is directly relevant to the haematopoietic stem cell biology this newsletter has covered since Issue 3. The publication date is stated explicitly so readers can weigh its currency accordingly.

Researchers led by Saghi Ghaffari identified lysosomal hyperactivation as a primary driver of ageing in haematopoietic stem cells in mice. Lysosomes are the cell's recycling structures, breaking down and processing cellular waste. As HSCs age, their lysosomes become overactive and damaged, triggering inflammation and reducing the stem cells' ability to regenerate blood and immune cells. Suppressing that hyperactivation with a vacuolar ATPase inhibitor restored youthful function to aged stem cells, including an eightfold increase in blood-forming ability when cells were treated ex vivo and returned to living animals.

Study type: Preclinical, mice only - no human data

What they found: Lysosomal dysfunction is a key mechanism of HSC ageing, and suppressing it restores regenerative capacity in aged murine stem cells

Most important caveat: Mouse models do not reliably predict human outcomes. No human trials are underway or announced.

Why it matters anyway: If the lysosomal mechanism translates to humans, it has implications for transplant outcomes in older patients and for age-related blood disorders. The team is now exploring whether the same lysosomal dysfunction contributes to leukaemic stem cell formation, potentially connecting normal ageing to cancer development. That is the more clinically significant question to watch.

A warning letter is a formal written communication from the FDA identifying specific regulatory violations and giving the recipient an opportunity to respond. It is not a recall, a fine, a criminal finding, or a shutdown order.

Recipients typically have 15 working days to respond with a plan to address the violations. If they do not respond adequately, the FDA may escalate: seizing products, seeking a court injunction, or referring the case to the Department of Justice. Many warning letters result in the recipient modifying their website or practices. Some do not.

The FDA publishes warning letters publicly. It does not routinely publish what happened next. A clinic that received a warning letter three years ago and changed its website copy is in the same public database as one that ignored the letter entirely. The letter tells you the violation was identified, not whether it was resolved.

Searching "FDA warning letters stem cell" at FDA.gov returns the current database. It is worth knowing it exists.

The FDA warning letter database contains more than 400 letters sent to stem cell and related product operators since 2018. Each one documents a specific gap between a claim and the evidence behind it. The majority of clinics that received them are still open.